BACKGROUND AND AIMS: Pituitary dysfunction including growth hormone (GH) deficiency may be associated with non-alcoholic fatty liver disease (NAFLD). Since the relationships among GH, IGF-1, IGFBP-3, and development of NAFLD without hypopituitarism are unclear, we examined the role of these hormones in the development of NAFLD based on clinical, laboratory and liver histology data. PATIENTS AND METHODS: A total of 55 consecutive patients (20 males and 35 females) with NAFLD. RESULTS: Aspartate amino transferase (AST), AST/ALT, platelet count and IGF-1, levels were significantly associated with differences in fibrosis, since these variables differed between stage 0-1 and stage 2-3 NAFLD. In multivariate analysis, platelet count (P = 0.0223, relative risk (RR), 5.899; 95% confidence interval (CI), 1.288-27.017), and IGF-1 (P = 0.0363, RR, 4.568; 95% CI, 1.101-18.945) showed significant associations with stage 2-3 NAFLD. Additionally, hyaluronic acid levels had a negative relationship with IGF-1 and the IGF-1/IGFBP-3 ratio. There was no relationship of fibrosis with GH level, but decreased GH (P = 0.0414, RR, 0.199; 95% CI, 0.042-0.989) was significantly associated with steatosis of stage 2-3. Low GH/IGF-1 and GH/IGFBP-3 ratios were found in advanced steatosis. CONCLUSION: GH, IGF-1 and IGFBP-3 are associated with hepatic fibrosis and steatosis in NAFLD. Low levels of IGF-1 might be associated with fibrosis while low level of GH with hepatic steatosis.
BACKGROUND AND AIMS: Pituitary dysfunction including growth hormone (GH) deficiency may be associated with non-alcoholic fatty liver disease (NAFLD). Since the relationships among GH, IGF-1, IGFBP-3, and development of NAFLD without hypopituitarism are unclear, we examined the role of these hormones in the development of NAFLD based on clinical, laboratory and liver histology data. PATIENTS AND METHODS: A total of 55 consecutive patients (20 males and 35 females) with NAFLD. RESULTS:Aspartate amino transferase (AST), AST/ALT, platelet count and IGF-1, levels were significantly associated with differences in fibrosis, since these variables differed between stage 0-1 and stage 2-3 NAFLD. In multivariate analysis, platelet count (P = 0.0223, relative risk (RR), 5.899; 95% confidence interval (CI), 1.288-27.017), and IGF-1 (P = 0.0363, RR, 4.568; 95% CI, 1.101-18.945) showed significant associations with stage 2-3 NAFLD. Additionally, hyaluronic acid levels had a negative relationship with IGF-1 and the IGF-1/IGFBP-3 ratio. There was no relationship of fibrosis with GH level, but decreased GH (P = 0.0414, RR, 0.199; 95% CI, 0.042-0.989) was significantly associated with steatosis of stage 2-3. Low GH/IGF-1 and GH/IGFBP-3 ratios were found in advanced steatosis. CONCLUSION:GH, IGF-1 and IGFBP-3 are associated with hepatic fibrosis and steatosis in NAFLD. Low levels of IGF-1 might be associated with fibrosis while low level of GH with hepatic steatosis.
Authors: Gail A Laughlin; Elizabeth Barrett-Connor; Michael H Criqui; Donna Kritz-Silverstein Journal: J Clin Endocrinol Metab Date: 2004-01 Impact factor: 5.958
Authors: Yosif Manavski; Tobias Abel; Junhao Hu; Dina Kleinlützum; Christian J Buchholz; Christina Belz; Hellmut G Augustin; Reinier A Boon; Stefanie Dimmeler Journal: Proc Natl Acad Sci U S A Date: 2017-03-27 Impact factor: 11.205
Authors: Daniela Catalano; Guglielmo M Trovato; Giuseppe Fabio Martines; Clara Pirri; Francesca M Trovato Journal: Hepatol Int Date: 2011-01-28 Impact factor: 6.047
Authors: Shauna S Runchey; Edward J Boyko; George N Ioannou; Kristina M Utzschneider Journal: J Gastroenterol Hepatol Date: 2014-03 Impact factor: 4.029
Authors: Muhsin Kaya; Devran Işık; Remzi Beştaş; Osman Evliyaoğlu; Veysi Akpolat; Hüseyin Büyükbayram; Mehmet Ali Kaplan Journal: World J Hepatol Date: 2013-11-27
Authors: Juan P Arab; Daniel Cabrera; Tejasav S Sehrawat; Nidhi Jalan-Sakrikar; Vikas K Verma; Douglas Simonetto; Sheng Cao; Usman Yaqoob; Jonathan Leon; Mariela Freire; Jose I Vargas; Thiago M De Assuncao; Jung H Kwon; Yi Guo; Enis Kostallari; Qing Cai; Tatiana Kisseleva; Youngman Oh; Marco Arrese; Robert C Huebert; Vijay H Shah Journal: J Hepatol Date: 2020-02-20 Impact factor: 25.083